Correction to: Clinical impact and cost-consequence analysis of ePlex® blood culture identification panels for the rapid diagnosis of bloodstream infections: a single-center randomized controlled trial
European Journal of Clinical Microbiology & Infectious Diseases · 2024-11 · 43 (11) · 2245-2246
DOI: 10.1007/s10096-024-04924-6 ↗Kurz gefasst
Korrektur in der Zeitschrift European Journal of Clinical Microbiology & Infectious Diseases, online erschienen am 29.08.2024. Verfasst von Yvan Caspar und 17 weiteren Autor:innen. Beteiligte Einrichtung: Laboratoire de Bactériologie-Hygiène Hospitalière, CHU Grenoble Alpes, Grenoble, France. YCaspar@chu-grenoble.fr. Die Arbeit wurde bisher 3-mal zitiert (Crossref). Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
transmission of positivity and Gram stain results from the first positive BC.Results This percentage was significantly higher in the multiplex PCR (mPCR) group (90/105 = 85.7% %, CI95% [77.5 ; 91.8] vs. 68/107 = 63.6%,CI95% [53.7 ; 72.6]; p < 10 -3 ) at interim analysis, resulting in the early termination of the study after the inclusion of 309 patients.For patients not optimized at baseline, the median time to obtain an optimized therapy was much shorter in the mPCR group than in the control group (6.9 h, IQR [2.9; 17.8] vs. 26.4h, IQR [3.4; 47.5]; p = 0.001).Early optimization of antibiotic therapy resulted in a non-statistically significant decrease in mortality from 12.4 to 8.8% (p = 0.306), with a trend towards a shorter median length of stay (18 vs. 20 days; p = 0.064) and a non-significant reduction in the average cost per patient of €3,065 (p = 0.15).mPCR identified all the bacteria present in 88% of the samples.
Autor:innen und Institutionen
- Laboratoire de Bactériologie-Hygiène Hospitalière, CHU Grenoble Alpes, Grenoble, France. YCaspar@chu-grenoble.fr.
- Univ. Grenoble Alpes, CNRS, CHU Grenoble Alpes, CEA, IBS, Grenoble, 38000, France. YCaspar@chu-grenoble.fr.
- Laboratoire de Bactériologie-Hygiène Hospitalière, CHU Grenoble Alpes, Grenoble, France.
- Service des Maladies infectieuses et tropicales, CHU Grenoble Alpes, Grenoble, France.
- Univ. Grenoble Alpes, CNRS, CHU Grenoble Alpes, CEA, IBS, Grenoble, 38000, France.
- Univ. Grenoble Alpes, CNRS, UMR 5525, VetAgro Sup, Grenoble INP, CHU Grenoble Alpes, TIMC, Grenoble, 38000, France.
Zitieren
APA
Caspar, Y., Deves, A., Richarme, C., Le Marechal, M., Ponderand, L., Mounayar, A. L., Lejeune, S., Arata-Bardet, J., Gallouche, M., Recule, C., Maubon, D., Garnaud, C., Cornet, M., Veloso, M., Chabani, B., Maurin, M., David-Tchouda, S., & Pavese, P. (2024). Correction to: Clinical impact and cost-consequence analysis of ePlex® blood culture identification panels for the rapid diagnosis of bloodstream infections: a single-center randomized controlled trial. European Journal of Clinical Microbiology & Infectious Diseases, 43(11), 2245-2246. https://doi.org/10.1007/s10096-024-04924-6
Vancouver
Caspar Y, Deves A, Richarme C, Le Marechal M, Ponderand L, Mounayar AL, et al. Correction to: Clinical impact and cost-consequence analysis of ePlex® blood culture identification panels for the rapid diagnosis of bloodstream infections: a single-center randomized controlled trial. European Journal of Clinical Microbiology & Infectious Diseases. 2024;43(11):2245-2246. doi:10.1007/s10096-024-04924-6
BibTeX
@article{Caspar2024,
author = {Caspar, Yvan and Deves, A and Richarme, C and Le Marechal, M and Ponderand, L and Mounayar, A-L and Lejeune, S and Arata-Bardet, J and Gallouche, M and Recule, C and Maubon, D and Garnaud, C and Cornet, M and Veloso, M and Chabani, B and Maurin, M and David-Tchouda, S and Pavese, P},
title = {Correction to: Clinical impact and cost-consequence analysis of ePlex® blood culture identification panels for the rapid diagnosis of bloodstream infections: a single-center randomized controlled trial},
journal = {European Journal of Clinical Microbiology & Infectious Diseases},
year = {2024},
volume = {43},
number = {11},
pages = {2245--2246},
doi = {10.1007/s10096-024-04924-6}
}
EUVIMED